1118567-05-7

1118567-05-7 structure

Name: Bexagliflozin
Chemical Name: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
CAS Number: 1118567-05-7
Molecular Formula: C₂₄H₂₉ClO₇
Molecular Weight: 464.936
Catalog: Signaling Pathways Membrane Transporter/Ion Channel SGLT
Create Date: 2018-04-12 08:00:00
Modify Date: 2024-01-02 11:31:57
Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.target: SGLT2IC50: 5.6 μM (SGLT1)/ 2 nM (SGLT2)1) In normal rats and dogs a saturable urinary glucose excretion was produced with an ED50 of 0.38 and 0.09 mg/kg, respectively.2) EGT1442 significantly prolonged the median survival of SHRSP rats.3) EGT1442 dose-dependently reduced HbA1c and blood glucose concentration without affecting body mass or insulin level.

Name	(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Synonyms	THR-1442 (1S)-1,5-Anhydro-1-(4-chloro-3-{4-[2-(cyclopropyloxy)ethoxy]benzyl}phenyl)-D-glucitol EGT0001442 UNII:EY00JF42FV THR1442 bexagliflozin D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-, (1S)- EGT1442

Description	Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.target: SGLT2IC50: 5.6 μM (SGLT1)/ 2 nM (SGLT2)1) In normal rats and dogs a saturable urinary glucose excretion was produced with an ED50 of 0.38 and 0.09 mg/kg, respectively.2) EGT1442 significantly prolonged the median survival of SHRSP rats.3) EGT1442 dose-dependently reduced HbA1c and blood glucose concentration without affecting body mass or insulin level.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT Research Areas >> Metabolic Disease
References	[1]. Zhang W et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res. 2011 Apr;63(4):284-93.